Stock report · Delisted · Nasdaq
Coeptis Therapeutics Inc (COEP)
16.40USD Delisted Final close · Apr 24, 2026
COEP no longer trades. Coeptis Therapeutics was delisted from the Nasdaq in April 2026.
All prices on this page are historical. The last trade was on April 24, 2026, at $16.40.
COEP stock price history
Final trading statistics
- Final close
- $16.40
- Final trading day
- Apr 24, 2026
- Market cap at delisting
- $102.06M
- Shares outstanding
- 6.22M
- Final 52-week range
- $6.26 – $21.41
- Avg. volume (final 3 mo.)
- 51,489
- All-time high
- $130.00 · Oct 2022
- All-time low
- $0.00 · Oct 2022
- Return since IPO
- +1366566.7%
- Beta
- -0.43
- Book value / share
- $2.36
- Price / book
- 6.95
About Coeptis Therapeutics Inc
Coeptis Therapeutics Holdings, Inc. and its subsidiaries formed a biopharmaceutical and technology business developing cell therapy platforms for cancer, autoimmune and infectious diseases. Its assets included an allogeneic cell immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy.
The pipeline included CD38-GEAR-NK for CD38-related cancers such as multiple myeloma, chronic lymphocytic leukemia and acute myeloid leukemia; CD38-Diagnostic, a lab test to see whether patients may suit anti-CD38 antibody therapy; and SNAP-CAR, a CAR therapy for cancer. It also offered drugs for acute myeloid leukemia and acute respiratory diseases.
Under a deal with Vici Health Sciences, LLC, it co-developed and shared rights to CPT60621 for Parkinson's Disease. Founded in 2017 and based in Wexford, Pennsylvania, the company was acquired by Z Squared Inc. in a reverse merger as of April 24, 2026. It was delisted from the Nasdaq in April 2026, last trading on April 24, 2026 at $16.40.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Wexford, PA
- Employees
- 4
- IPO date
- December 17, 2020
- Delisted
- April 24, 2026
- SEC CIK
- 1819663
Coeptis Therapeutics financials before the delisting
The last 5 fiscal years Coeptis Therapeutics reported as a public company, fiscal year ending December.
COEP revenue and net income
COEP earnings per share
COEP annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $1.36M | −$11.9M | — |
| FY2024 | $0.00 | −$10.7M | −$4.29 |
| FY2023 | $0.00 | −$21.3M | −$14.75 |
| FY2022 | $0.00 | −$37.6M | −$2.81 |
| FY2021 | $75.0K | −$13.4M | $1.80 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Coeptis Therapeutics stock FAQ
What happened to Coeptis Therapeutics stock?
Coeptis Therapeutics was delisted from the Nasdaq in April 2026. The final close was $16.40 on April 24, 2026.
Can I still buy COEP stock?
No. COEP is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on April 24, 2026.
What was the last price of COEP?
COEP last closed at $16.40 on April 24, 2026, which valued the company at about $102.06M.
How did Coeptis Therapeutics do in its last full fiscal year?
In fiscal 2025, its last full year as a public company, Coeptis Therapeutics reported revenue of $1.36M and net income of −$11.9M.
When did Coeptis Therapeutics go public?
Coeptis Therapeutics shares started trading on December 17, 2020.
COEP no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.